RxDoctor Payments Data

Graceanna Baker, APRN

Family · Greenville, SCNPI 1174166169

Payments from drug & device makers

$2,172in general payments, 2019–2025

Across 49 payments — averaging $44.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$965
  • Merck$413
  • Eisai Inc.$235
  • Genmab U.S., Inc.$168
  • Baxter Healthcare$116
  • Myriad Genetic Laboratories, Inc.$94
  • plus $181 from 5 others

What the payments were for

  • Travel & lodging$76935%
  • Food & beverage$1,36763%
  • Education$362%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,172 in reported general payments places this provider in the 80th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$27,805
Medicare patients
197
Services billed
412

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LenvimaLenvatinib Mesylate18$422,943
Prochlorperazine Maleate64$1,099
Dexamethasone105$883
Pregabalin39$818
Anastrozole21$577
Ondansetron Hcl59$453
Medroxyprogesterone Acetate15$424
Megestrol Acetate13$381
Nystatin22$330
Lidocaine-PrilocaineLidocaine/Prilocaine27$310
Klor-Con M20Potassium Chloride11$185
Gabapentin17$81
Ciprofloxacin Hcl25$74
Cephalexin12$24
Tramadol Hcl12$16

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Eisai Inc.Lenvima$235$422,94318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,248 family providers in South Carolina.

Other family in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →